MRK trade ideas
lookin good MRK helping JNJ w the vaccine, at great support, can be looked at with a huger reverse head and shoulders
april earnings
looking good
After six-week slide, I am buying MerckMerck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several years.
Merck's valuation is quite attractive for a growing, large-cap company. I estimate its forward P/E at 10, forward P/S at 3.4, and PEG under 5. Merck's dividend yield is a juicy 3.76%, and they should have no problem sustaining that given their free cash flow growth. I estimate that Merck has about 16% upside to its median price multiple of the last four years.
Market sentiment is quite bullish on Merck. The average analyst summary score is a "buy" at 6.4/10. Merck has about 30% upside to its average analyst price target. Open interest from option traders is in highly bullish territory, with a put-call ratio of 0.56.
News lately has been a bit negative for Merck. Today they voluntarily withdrew their drug Keytruda for one of its (many) indications because it didn't meet FDA post-marketing requirements. That's not great, but it won't be devastating to Keytruda revenues. Merck's proposed purchase of Pandion Therapeutics is being investigated for procedural problems, which also isn't great. Plus, the FDA delayed approval of Merck's application for emergency approval for its Covid-19 drug until it produces more data.
On the other hand, Merck just submitted a New Drug Application for gefapixant and cut a billion-dollar commercialization deal for Xevinapant. Both those things are positives for the company. Plus, Merck got some positive attention recently due to a large purchase of its stock by Warren Buffett's investment fund.
In technical terms, Merck obviously has been in a downtrend, but it's approaching trend line support. I'm looking at buy tomorrow in the $71.50-71.75 range if Merck continues to dip toward support.
MRK, longClose to multi-years support box. Buying accumulation in the past days. Reversal is expected on a stronger SPY.
MRK bounce trade + Long term holdWarrent buffet, need I say more.
He had been buying these throughout 2020 at these levels, so I can presume this is fair value.
Additionally, I am, as a swing trader, looking into the call options on LEAP to selll when they are near the top of range.
looking at 1-3 of them here
Bottom FishingHow long will she go? Yearly low is 65.25.
Price has pierced bottom bollinger band set on 80 moving average. I noted MRK has done this before, but stayed below a while earlier this year, and drifted back inside as most always do. Some can fall out further than others before drifing back to the mean. Possible double bottom unless another low is made.
Last daily candle is a hammer
Not a recommendation
Bullish Crab MRK - 4H chart formed harmoic pattern called Crab
BUY 75.60 to 76.45
T1 79.35
T2 81.70
SL closing below 74.00
MRK coming back from SupportComing back from Support, daily engulfing candle, 4 hr two strong candle...
buy slowly looking at the trend, target can be $78 or higher.
MRK LongCompany Profile: Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Top Institutional Holders:
Holder Shares
Vanguard Group, Inc. (The) : 209,865,924
Blackrock Inc. : 195,017,904
State Street Corporation : 117,030,114
MRK Swing Trade Triple Bottom IdeaMRK seems to be revearsing from here, RSI is oversold, Stochastic RSI is showing a Bullish crossover and a Triple Pattern seems to be forming.
Entry Price = $75, SL = $73, TP = $83
MKT ReversalThe case for a bull swing reversal (1 week):
RSI Low
Yearly support level reached
Momentum going up
Short interest to cover in 2 days
Entry
Current price: (~$74.8)
Stop
Local low (~$74.225)
Target
~MVWAP / Fib 50%
Profit
~$3 USD per share
Risk
1.2%
Risk/Reward Ratio
2.4
MRK - Tripple bottom bounce - target $82Expect to bounce off from $74.
Target 82.
———————————————————
How to read my charts?
- Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines.
- The yellow horizontal lines shows support and resistance areas.
- Fib lines also shows support and resistance areas.
- The dotted white lines shows price projection for breakout or breakdown target.
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But...
MRK
BUYZONE = 74 - 76
Cost Avg Down (CAD) = 72 - 70
1st Target = 79
2nd Target = 82
3rd Target = 86
HODL Target = ATH
______________________________________________________________________________________________________________________
This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice.
Good luck, happy trading and stay chill,
2degreez
MRK has a potential to fallIf MRK falls below the support level indicated by the white horizontal line I think it will continue to fall lower.
Buy $MRK - NRPicks Feb 07Merck & Co, Inc. provides healthcare solutions worldwide. The company offers treatments for cardiovascular disease, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal infections, fungal infections, insomnia and inflammatory diseases; neuromuscular blocking agents; cholesterol-modifying drugs; and vaginal contraceptive and antibacterial products.
Merck is one of the companies that had been selected to develop the vaccine; however, it is still a company with a very high level team of workers and successful products. In terms of its finances, its debt is average relative to industry-competitors, plus it generates enough cash to be able to meet those obligations.
Fundamentals:
- Growth
- 6% estimated growth in net earnings for the next 3 years.
- ROE 50.5% VS 17% industry.
Technicals:
- Price level below SMA 250-200-150
- Williams R% at -78% levels
- RSI (36) Oversold
-1.5% average upside during the month
A correction of 11% was presented from JANUARY 12 to FEBRUARY 5, which stopped at $75.45 support. The correction was presented because the company abandoned the development of the vaccine against COVID, from the support the stock has shown a change of trend. Finally, the technical indicators are favorable and give us a buy signal.
MRK Technical Analysis 🧙Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
$MRK bear trend will break after (at least) one more swing high.Most of the research is on the page but I'll explain it briefly.
The past two clear trends have shown four swing highs before a break (up/down is irrelevant) - the current bearish trend has only seen three swing highs so far.
The RSI of the market is low, which usually foreshadows a bullish movement, if you want to argue that the swing high at $84.70 also counts as a swing high in our current bearish trend, then we are just about due for a bullish sprint.
I personally don't think we've seen enough swing lows (see previous bear trend) for a momentum break, especially considering that the current trend has the change in CEO & financial report as a catalyst whereas the previous one simply had the financial statement creating momentum.
MERCK $ CO Accurate Analysis When the first ABC correction was over we saw the bearish move. Now a smaller ABC correction may be finished and we can expect the next move. I will keep updating this chart if necessary. Comment, like follow for more accurate ideas. Thank you
Traditional|MRK|Long and short *High riskLong and short MRK
Activation of the transaction only when the blue zone is fixed/broken.
Working out the local support and resistance levels of the triangle.
The "forecast" tool is used for more noticeable display of % (for the place of the usual % scale) of the price change, I do not put the date and time of the transaction, only %.
The breakdown of the upper blue zone - long.
Breakdown of the lower blue zone - short.
Working out the stop when the price returns to the level after activation + fixing in the red zone.
Blue zones - activation zones.
Green zone - take zone.
The red zone - the stop zone.
Orange arrows indicate the direction of the take.
Red arrows indicate the direction of the stop.
